GET DAILY SIGNALSRapport Therapeutics (RAPP) Shares Decline -34% in 30 Days on Bipolar Mania Readout
Key Takeaways
- RAPP shares fell roughly 34% over the trailing 30 days, sliding from a closing price near $39.66 to approximately $26.
- The decline accelerated after a late-September reset in expectations around the RAP-219 bipolar mania readout.
- RAP-219 met its Phase 2 primary endpoint in bipolar mania, but the effect size landed below the "clinically meaningful" threshold management had previously cited, triggering a "sell the news" reaction.
- The stock is also down about 38% from three months earlier, despite a strong focal-onset-seizure data set and an enrolling Phase 3 program.
- A cash position of roughly $477 million at the end of the first quarter of 2026 and an expanding pipeline remain key offsets to near-term volatility.
Rapport Therapeutics (RAPP) Background and Positioning
Rapport Therapeutics is a clinical-stage biotechnology company developing small-molecule precision medicines for neurological and psychiatric disorders. Founded in 2022 and based in Boston, the company completed its initial public offering on the Nasdaq in June 2024. Its RAP technology platform is built on discoveries around receptor-associated proteins (RAPs) that are expressed only in discrete regions of the brain, an approach intended to improve efficacy while reducing the off-target side effects common to conventional neuroscience drugs.
The company's lead candidate, RAP-219, is a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator. Because TARPγ8 is concentrated in the hippocampus and neocortex but minimally expressed in the hindbrain, Rapport positions RAP-219 as a "pipeline-in-a-product" with the potential to address focal onset seizures, primary generalized tonic-clonic seizures, bipolar mania, and other central nervous system conditions. Investors follow the stock closely because the readouts for RAP-219 across these indications could define a multi-billion-dollar commercial opportunity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance: 30 Days and the Quarter
Over the last 30 days, RAPP shares declined approximately 34%, moving from a close of about $39.66 on September 21 to near $26 in late-October trading. The move was not a single-day collapse but rather a steady de-risking punctuated by sharp sell-offs in late September and again around the October 20 bipolar mania readout.
The three-month picture is similar in direction but reflects more volatility. From a close of roughly $42.56 on July 21, the stock rallied to an intraday high near $52.50 in late August before giving back those gains. By late October the shares traded near $26, leaving the stock down approximately 38% over the quarter despite a strong Phase 2a epilepsy data set and a fully enrolled Phase 3 program. From what I see, the pattern shows how quickly sentiment can shift even with solid underlying progress.
Key Drivers Behind the 30-Day Decline
The sharpest single catalyst within the 30-day window was management commentary in late September. At a TD Cowen neuropsychiatry event, Chief Executive Officer Abraham Ceesay described a four-point placebo-adjusted improvement on the Young Mania Rating Scale (YMRS) as the "clinically meaningful threshold" for the bipolar mania program. That reference reset investor expectations and coincided with a steep one-day sell-off as traders reassessed the probability of a differentiated result.
The second major catalyst arrived on October 20, 2026, when Rapport reported topline results from its Phase 2 trial of RAP-219 in acute bipolar mania. The drug met its primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in YMRS total score at Week 3 (p=0.045) and also achieved a prespecified secondary endpoint. The therapy was well tolerated, with no severe treatment-emergent adverse events reported. However, the 3.1-point effect fell short of the four-point bar the company itself had flagged, and it sat at the low end of the three-to-four-point range historically delivered by approved therapies. Shares spiked in premarket trading before reversing sharply, a classic "sell the news" reaction driven by the modest magnitude of the effect rather than a clinical failure. One thing that stands out here is how the market weighed the statistical win against prior guidance.
Quarter-Long Factors Influencing RAPP
The quarter's broader narrative combines positive pipeline progress with profit-taking and pre-readout de-risking. In April 2026, follow-up data from the Phase 2a focal-onset-seizure trial presented at the American Academy of Neurology meeting showed a 90% median reduction in clinical seizures in the first four weeks after dosing ended, reinforcing confidence in the epilepsy program. Phase 3 FOCUS 1 and FOCUS 2 trials began enrolling in the second quarter.
That progress attracted constructive analyst coverage, including price-target increases from BTIG, Raymond James, and H.C. Wainwright, as well as new Buy initiations. The stock rallied to multi-month highs near $52.50 in late August. Yet a sizable insider sale by venture investor Third Rock Ventures, a second-quarter earnings miss, and a broader pullback in speculative biotech sentiment contributed to the subsequent decline. By late October, the optimism built around the bipolar mania readout had largely unwound as investors weighed a statistically positive but modestly sized result against elevated expectations. I reviewed recent patterns around similar events with Tickeron’s AI Real Time Patterns to put the moves in context.
Upcoming Catalysts for RAPP Investors
Looking ahead, the most important catalyst for RAPP is the progress of the FOCUS 1 and FOCUS 2 Phase 3 trials in focal onset seizures, which will ultimately determine whether RAP-219 can reach the market. Investors are also watching the planned FDA meeting in the first quarter of 2027 to discuss the registrational design for the bipolar mania program, with Phase 3 trials in that indication expected to begin in the second half of 2027.
Additional data catalysts include initial results from the open-label extension study in the second half of 2026, a Phase 3 program in primary generalized tonic-clonic seizures expected to begin in the first half of 2027, and initial pharmacokinetic results for a long-acting injectable formulation in 2027. Near-term quarterly earnings will also be closely watched, as will the company's ability to preserve its cash runway, which management has guided into the second half of 2029. As with all clinical-stage biotech companies, trial outcomes, regulatory decisions, and financing conditions carry meaningful risk.
AI Tools for Navigating Volatile Biotech Names
For traders who prefer a data-driven approach to navigating volatile names like RAPP, Tickeron’s Trending AI Robots page offers a curated view of AI-powered trading strategies. I find it useful to review the top-performing bots here when assessing how systematic signals align with fundamental developments in clinical-stage names. The section highlights bots with different strategies and timeframes, letting users match approaches to their own risk tolerance while staying grounded in recent performance data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RAPP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RAPP turned positive on October 19, 2026. Looking at past instances where RAPP's MACD turned positive, the stock continued to rise in 27 of 29 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RAPP's RSI Oscillator exited the oversold zone, 3 of 5 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
Following a +6.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where RAPP advanced for three days, in 124 of 140 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
RAPP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for RAPP crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RAPP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for RAPP entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.332) is normal, around the industry mean (3.009). P/E Ratio (-9.693) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (92.593) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. RAPP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RAPP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement